Home > Investment and Entrepreneurship> Key Projects

Biomedicine in SSGKC

Updated : 2018-11-19

GE BioPark Campus Project

General Electric (GE) BioPark is a creation of GE Healthcare headed by GE, a Global 500 company, with a total investment of US $400 million. GE BioPark, responsible for the design, construction, and operation of the park's public facilities, offers public platforms and technical support services, where biopharmaceutical companies produce monoclonal antibody biopharmaceuticals through the purchase of GE's KUBio modular biomanufacturing facilities. The estimated output value is 4 to 8 billion US dollars during the operation.

BeiGene Project

BeiGene project is funded and built by NASDAQ-listed company BeiGene, with an investment budget of about 2.3 billion yuan. It is part of a plan to build a production base of PD-1 monoclonal antibody biopharmaceuticals, which consists of three sets of GE's KUBio modular biomanufacturing facilities. Once completed, the project is expected to have an output value of about 9.8 billion yuan in the first year, and an output value of about 20 billion yuan during operation.

InnoCare Guangzhou Development Center Project

InnoCare Guangzhou Development Center, with a total investment of 2.1 billion yuan, was cofounded by Beijing InnoCare Pharma. InnoCare is a national leading platform dedicated to novel treatments for cancer and autoimmune diseases. It is headed by Dr. Jasmine Cui (President & CEO), who is an internationally recognized expert in those novel treatments and translational medicine and a member of the Scientific Advisory Board (SAB) chaired by the distinguished structural biologist Dr. Shi Yigong. A biopharmaceutical enterprise introduced by Huangpu District and Guangzhou Development District (GDD), Beijing InnoCare Pharma will establish an industrialization base-oriented whole industry chain covering new drug R&D, talent cultivation, production and sales, to produce globally patented Class I new drugs for targeting cancer and autoimmune diseases. It will accelerate the building of biomedical industry clusters and a leading center of world-class health industries.

Luye Life Sciences Industrial Park

Luye Life Sciences (Guangzhou) Co., Ltd. is registered in SSGKC with a registered capital of 1 billion yuan. Luye Life Sciences plans to invest 6 billion yuan into the park, which and will put its sectors such as R&D centers, medical centers, molecular diagnostics, and regenerative medicine in place which will maximize the effect of its industry chain.

Akeso Biopharma Project

Funded by Akeso Biopharma with a total investment of about 2 billion yuan, the project is dedicated to the development of innovative antibody drugs with independent intellectual property rights and R&D driven innovative biologics, and intends to gradually grow into a large-scale pharmaceutical enterprise integrating R&D, pilot test, production and sales. The total investment of the project is 700 million yuan, and it is estimated that the annual operating income will reach 5 billion yuan.

Copyright © Guangzhou Development District People's Government.
All rights reserved. Presented by China Daily